News

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ ...
Alamar Biosciences, Inc.: Alamar Biosciences joins forces with SciLifeLab to advance understanding of human disease
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease is proud to announce a strategic collaboration ...
Alamar Biosciences, Inc.: Alamar Biosciences Expands NULISAseq CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative ...
Morningstar27d
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting
Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel ...
The Victoria Advocate23d
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE ... the value INGREZZA may bring to patients, and the Company's plans to encourage awareness that may help address the ...
Morningstar23d
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
TD is estimated to affect at least 800,000 adults in the U.S. About Neurocrine Biosciences, Inc. The NEUROCRINE BIOSCIENCES Logo ... inhibitor and the Company's plans to encourage awareness ...
Woolly mice and "dire wolves" are a distraction from attacks on endangered species, experts caution
"De-extinction" takes center stage as environmentalists express dismay over erosion of the Endangered Species Act ...
Longview News-Journal21d
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing ...
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE and YOU DESERVE BRAVE ... risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and ...
A 30-foot statue? Genetically modified mammoth? Here is what could be in store for Utah’s NHL team.
A 30-foot statue? Genetically-modified mammoth? Here is what could be in store for Utah’s NHL team following its rebrand.
Market Shrugs Off This Drugmaker's Turnaround
This drugmaker achieved a milestone - its first quarterly profit. But the stock is down despite the good tidings.